Jongchan Kim
Yonsei University
28 Papers
71 Citations
Jongchan Kim is an academic researcher from Yonsei University. The author has contributed to research in topics: Medicine & Nephrectomy. The author has an hindex of 9, co-authored 28 publications. Previous affiliations of Jongchan Kim include University Health System.
Chat about Author
Papers
Recent Global Trends in Testicular Cancer Incidence and Mortality
TL;DR: While the incidence ofTCa has increased, mortality from TCa has decreased in most countries, with more socioeconomically developed countries had a higher incidence of TCa with lower mortality.
254
Real-time simultaneous endoscopic combined intrarenal surgery with intermediate-supine position: Washout mechanism and transport technique
Hae Do Jung,Jongchan Kim,Hyun Kyu Ahn,Joon Ho Kwon,Kichang Han,Woong Kyu Han,Man Deuk Kim,Joo Yong Lee +7 more
TL;DR: The experience and advantages of real-time simultaneous ECIRS are shared and techniques to increase the stone-free rate are introduced to reduce patient's burden and prevent an anesthesiologic problem.
44
External validation of the RENAL nephrometry score nomogram for predicting high-grade renal cell carcinoma in solid, enhancing, and small renal masses.
TL;DR: The RNS nomogram may be unreliable for preoperatively predicting high-grade RCC in SRMs, in which tumor size, the key determinant of high- grade RCC, is a limiting factor.
26
Risk Prediction Tool for Aggressive Tumors in Clinical T1 Stage Clear Cell Renal Cell Carcinoma Using Molecular Biomarkers
TL;DR: Molecular biomarkers associated with aggressive clinical T1 stage ccRCCs of ≤7 cm were investigated and used to develop a risk prediction tool toward guiding the decision of treatment, which demonstrated the significant downregulation of FOXC2, PBRM1, and BAP1 expression in aggressive CCRCC.
26
The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.
TL;DR: Review of the available studies suggests that stereotactic radiotherapy of metastatic lesions in oligorecurrent disease is a feasible and safe modality for managing oligometastatic prostate cancer.
25